New Data on POSLUMA® (Flotufolastat F 18) in Patients with Suspected Biochemical Recurrence of Prost
− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered –For U.S audiences onlyMONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in...